Joshua Kemp

Psychology University of Wyoming, Laramie, WY, United States 
"Joshua Kemp"
Mean distance: 13939
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kemp JJ, Blakey SM, Wolitzky-Taylor KB, et al. (2019) The effects of safety behavior availability versus utilization on inhibitory learning during exposure. Cognitive Behaviour Therapy. 1-12
Farrell NR, Kemp JJ, Blakey SM, et al. (2016) Targeting clinician concerns about exposure therapy: A pilot study comparing standard vs. enhanced training. Behaviour Research and Therapy. 85: 53-59
Dixon LJ, Kemp JJ, Farrell NR, et al. (2015) Interoceptive exposure exercises for social anxiety. Journal of Anxiety Disorders. 33: 25-34
Kemp JJ, Lickel JJ, Deacon BJ. (2014) Effects of a chemical imbalance causal explanation on individuals' perceptions of their depressive symptoms. Behaviour Research and Therapy. 56: 47-52
Meyer JM, Farrell NR, Kemp JJ, et al. (2014) Why do clinicians exclude anxious clients from exposure therapy? Behaviour Research and Therapy. 54: 49-53
Deacon B, Kemp JJ, Dixon LJ, et al. (2013) Maximizing the efficacy of interoceptive exposure by optimizing inhibitory learning: a randomized controlled trial. Behaviour Research and Therapy. 51: 588-96
Deacon BJ, Farrell NR, Kemp JJ, et al. (2013) Assessing therapist reservations about exposure therapy for anxiety disorders: the Therapist Beliefs about Exposure Scale. Journal of Anxiety Disorders. 27: 772-80
Farrell NR, Deacon BJ, Kemp JJ, et al. (2013) Do negative beliefs about exposure therapy cause its suboptimal delivery? An experimental investigation. Journal of Anxiety Disorders. 27: 763-71
Deacon BJ, Lickel JJ, Farrell NR, et al. (2013) Therapist perceptions and delivery of interoceptive exposure for panic disorder. Journal of Anxiety Disorders. 27: 259-64
Lyon GJ, Samar SM, Conelea C, et al. (2010) Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. Journal of Child and Adolescent Psychopharmacology. 20: 283-9
See more...